

Augusta University Institutional Biosafety Committee (IBC)

Checklist for Human Gene Transfer/Therapy and/or DNA Vaccine Clinical Trial Protocols

The following is a list of requirements needed to comply with the NIH Recombinant DNA Guidelines, Appendix M for clinical trial protocols. http://oba.od.nih.gov/oba/rac/guidelines_02/APPENDIX_M.htm

- *Approval by another Institutional Biosafety Committee does not guarantee approval by Augusta University's IBC.*
- *All communications between a study sponsor and the IBC must be through the Principal Investigator or designee*

Submit documents below, including this checklist to biosafety@augusta.edu.

Requirements	Resource	Status
1 Biosafety Protocol (BSP) "Full" Application (A new one must be completed for each study, specific to that study. For these types of trials, one application cannot cover multiple studies, each requires a new application).	http://www.augusta.edu/research/ibc/apps.php If electronic signature is not possible, mail an original signature page.	
2 Curriculum vitae of PI and co-PI	HGT studies must have a co-PI	
3 Responses to NIH Recombinant DNA Guidelines, Appendix M	Must be PI and site-specific http://osp.od.nih.gov/sites/default/files/NIH_Guidelines_0.pdf	
4 FDA Approval	Explain if not applicable	
5 Relevant Correspondence with FDA	Explain if not applicable	
6 Investigator's Brochure	Explain if not applicable	
7 Information regarding rDNA and Standard Operating Procedures for its receipt, handling, transfer/transport, administration and proper disposal	Must be site-specific	
8 Preclinical Animal Data (if Phase 1)	Explain if not applicable	
9 Previous Human Data with Recombinant DNA	Explain if not applicable	
10 Clinical Protocol for the FDA	Explain if not applicable	
11 Consent Forms	Must be site-specific	
12 Annual Renewal Requirements	See Appendix M-I-C-3	

Contact EH&S Biosafety at 706-721-2663 or biosafety@augusta.edu for consultation as needed.